high altitude polycythemia
Conditions
Interventions
Experimental group1:Phlebotomy300ml QOD
Experimental group2:Phlebotomy400ml QOD
Control group:Phlebotomy200ml QOD
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
30 Years to 72 Years
Inclusion criteria
Inclusion criteria: (1) older than 18 years old (2) Living and working at a plateau above 2500m for a long time. (3) hemoglobin concentration =210 g/L in men and =190 g/L in women. (4) complicated with shortness of breath, palpitations, memory loss, sleep disorders, cyanosis, bulbar conjunctival hyperemia, headache (dizziness) and tinnitus. Meet at least one of the symptoms (signs) (5) Informed consent to accept the study protocol.
Exclusion criteria
Exclusion criteria: (1) pregnant and lactating women; (2) Polycythemia vera, sleep apnea syndrome, chronic heart failure, chronic respiratory failure, severe chronic airway diseases (COPD, asthma, bronchiectasis), chronic pulmonary heart disease, congenital heart disease and other underlying diseases leading to polycythemia. (3) Patients with severe condition can not be treated with bloodletting, such as unconscious patients, patients who need ventilator assisted ventilation, severe hypertension,hypotension and arrhythmia,severe brain,heart,lung,liver and kidney dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of reaching the standard of 3 times of bloodletting;Significant improvement rate of CMS score after 3 exsanguination sessions; | — |
Secondary
| Measure | Time frame |
|---|---|
| rate of recurrent HAPC at 30, 90, and 180 days After the last exsanguination; | — |
Countries
China
Contacts
Public ContactFengming Luo
West China Hospital, Sichuan University
Outcome results
None listed